Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Non Operating Income (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Non Operating Income for 4 consecutive years, with $81889.0 as the latest value for Q4 2024.

  • Quarterly Non Operating Income fell 30.32% to $81889.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $345378.0 through Dec 2024, down 14.73% year-over-year, with the annual reading at $429612.0 for FY2025, 24.39% up from the prior year.
  • Non Operating Income hit $81889.0 in Q4 2024 for Pasithea Therapeutics, up from $4770.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.6 million in Q4 2021 to a low of -$335317.0 in Q3 2022.
  • Historically, Non Operating Income has averaged $281815.2 across 4 years, with a median of $99540.0 in 2023.
  • Biggest five-year swings in Non Operating Income: tumbled 102.15% in 2022 and later soared 2916.75% in 2024.
  • Year by year, Non Operating Income stood at $2.6 million in 2021, then tumbled by 102.15% to -$55594.0 in 2022, then surged by 311.39% to $117518.0 in 2023, then tumbled by 30.32% to $81889.0 in 2024.
  • Business Quant data shows Non Operating Income for KTTA at $81889.0 in Q4 2024, $4770.0 in Q3 2024, and $78785.0 in Q2 2024.